Display options
Cite
Guengerich FP. Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications. Biomol Ther (Seoul). 2022;30(1):1-18doi: 10.4062/biomolther.2021.102.
Guengerich, F. P. (2022). Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications. Biomolecules & therapeutics, 30(1), 1-18. https://doi.org/10.4062/biomolther.2021.102
Guengerich, F Peter. "Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications." Biomolecules & therapeutics vol. 30,1 (2022): 1-18. doi: https://doi.org/10.4062/biomolther.2021.102
Guengerich FP. Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications. Biomol Ther (Seoul). 2022 Jan 01;30(1):1-18. doi: 10.4062/biomolther.2021.102. PMID: 34475272.
Copy Download .nbib Format: NLM
Share it on

Biomol Ther (Seoul). 2022 Jan 01;30(1):1-18. doi: 10.4062/biomolther.2021.102.

Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications.

Biomolecules & therapeutics

F Peter Guengerich

PMID: 34475272 DOI: 10.4062/biomolther.2021.102

Abstract

Drug-drug interactions are a major cause of hospitalization and deaths related to drug use. A large fraction of these is due to inhibition of enzymes involved in drug metabolism and transport, particularly cytochrome P450 (P450) enzymes. Understanding basic mechanisms of enzyme inhibition is important, particularly in terms of reversibility and the use of the appropriate parameters. In addition to drug-drug interactions, issues have involved interactions of drugs with foods and natural products related to P450 enzymes. Predicting drug-drug interactions is a major effort in drug development in the pharmaceutical industry and regulatory agencies. With appropriate

Keywords: CYP; Cytochrome P450; Drug-drug interactions; Enzyme inhibition; P450 inhibition

Publication Types

Grant support